<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:54:06Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3277821" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:3277821</identifier>
        <datestamp>2012-02-21</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id>
              <journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id>
              <journal-title-group>
                <journal-title>Investigational New Drugs</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0167-6997</issn>
              <issn pub-type="epub">1573-0646</issn>
              <publisher>
                <publisher-name>Springer US</publisher-name>
                <publisher-loc>Boston</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC3277821</article-id>
              <article-id pub-id-type="pmcid">PMC3277821</article-id>
              <article-id pub-id-type="pmc-uid">3277821</article-id>
              <article-id pub-id-type="pmid">20967484</article-id>
              <article-id pub-id-type="pmid">20967484</article-id>
              <article-id pub-id-type="publisher-id">9562</article-id>
              <article-id pub-id-type="doi">10.1007/s10637-010-9562-8</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Phase II Studies</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Li</surname>
                    <given-names>Tianhong</given-names>
                  </name>
                  <address>
                    <phone>+1-916-7343772</phone>
                    <fax>+1-916-7347946</fax>
                    <email>tianhong.li@ucdmc.ucdavis.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Christensen</surname>
                    <given-names>Scott D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Frankel</surname>
                    <given-names>Paul H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Margolin</surname>
                    <given-names>Kim A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Agarwala</surname>
                    <given-names>Sanjiv S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Luu</surname>
                    <given-names>Thehang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mack</surname>
                    <given-names>Philip C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lara</surname>
                    <given-names>Primo N.</given-names>
                    <suffix>Jr.</suffix>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gandara</surname>
                    <given-names>David R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label>Division of Hematology &amp; Oncology, University of California Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817 USA </aff>
                <aff id="Aff2"><label>2</label>City of Hope Comprehensive Cancer Center, Duarte, CA USA </aff>
                <aff id="Aff3"><label>3</label>University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA USA </aff>
                <aff id="Aff4"><label>4</label>Present Address: Seattle Cancer Center Alliance, Seattle, WA USA </aff>
                <aff id="Aff5"><label>5</label>Present Address: St. Luke’s Cancer Center, Bethlehem, PA USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>10</month>
                <year>2010</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>22</day>
                <month>10</month>
                <year>2010</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2012</year>
              </pub-date>
              <volume>30</volume>
              <issue>2</issue>
              <fpage>741</fpage>
              <lpage>748</lpage>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>9</month>
                  <year>2010</year>
                </date>
                <date date-type="accepted">
                  <day>3</day>
                  <month>10</month>
                  <year>2010</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2010</copyright-statement>
                <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
                  <license-p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <title>Summary</title>
                <p><italic>Background</italic> Genetic abnormalities in cell cycle control are common in malignant melanoma. UCN-01 (7-hydroxystaurosporine) is an investigational agent that exhibits antitumor activity by perturbing the cancer cell cycle. A patient with advanced melanoma experienced a partial response in a phase I trial of single agent UCN-01. We sought to determine the activity of UCN-01 against refractory metastatic melanoma in a phase II study. <italic>Patients and methods</italic> Patients with advanced melanoma received UCN-01 at 90 mg/m<sup>2</sup> over 3 h on cycle 1, reduced to 45 mg/m<sup>2</sup> over 3 h for subsequent cycles, every 21 days. Primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). A two-stage (17 + 16), single arm phase II design was employed. A true response rate of ≥20% (i.e., at least one responder in the first stage, or at least four responders overall) was to be considered promising for further development of UCN-01 in this setting. <italic>Results</italic> Seventeen patients were accrued in the first stage. One patient was inevaluable for response. Four (24%) patients had stable disease, and 12 (71%) had disease progression. As there were no responders in the first stage, the study was closed to further accrual. Median PFS was 1.3 months (95% CI, 1.2–3.0) while median OS was 7.3 months (95% CI, 3.4–18.4). One-year and two year OS rates were 41% and 12%, respectively. A median of two cycles were delivered (range, 1–18). Grade 3 treatment-related toxicities include hyperglycemia (<italic>N</italic> = 2), fatigue (<italic>N</italic> = 1), and diarrhea (<italic>N</italic> = 1). One patient experienced grade 4 creatinine elevation and grade 4 anemia possibly due to UCN-01. No dose modification was required as these patients had disease progression. <italic>Conclusion</italic> Although well tolerated, UCN-01 as a single agent did not have sufficient clinical activity to warrant further study in refractory melanoma.</p>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Metastatic melanoma</kwd>
                <kwd>UCN-01</kwd>
                <kwd>7-hydroxystaurosporine</kwd>
                <kwd>Cell cycle inhibitor</kwd>
                <kwd>Phase II</kwd>
                <kwd>Targeted therapy</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Science+Business Media, LLC 2012</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p>Melanoma is the sixth most common cancer in the United States, and the number of melanoma cases diagnosed annually is increasing faster than for any other cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. The management of patients with metastatic melanoma is a challenging clinical problem. Median survival time for patients with metastatic disease is approximately 6 months and less than 10% of patients will survive 5 years [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Despite the commercial availability of numerous agents to treat melanoma, standard therapy for this malignancy today is considered experimental (<ext-link ext-link-type="uri" xlink:href="http://www.nccn.org">www.nccn.org</ext-link>). Treatment approaches have traditionally included cytotoxic chemotherapy and immunotherapy, used either alone or in combination [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. However, these approaches have not improved outcomes in this disease, with the recent exception of the anti-CTLA4 agent ipilimumab [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, there is an unmet need to develop more effective approaches for the treatment of metastatic melanoma.</p>
              <p>Genetic abnormalities in cell cycle regulation, particularly G1-S checkpoint control, are common in melanoma [<xref ref-type="bibr" rid="CR8">8</xref>]. Regulation of G1 phase control consists of inhibition of cyclin-dependent kinases (CDKs) and upreguation of CDK inhibitors, with subsequent hypophosphorylation of the retinoblastoma (Rb) tumor suppressor protein. Particularly, disruption of the CDK inhibitors p21<sup>waf1/cip1</sup> (hereafter, p21) and p27<sup>kip1</sup> (hereafter, p21), and inactivation of tumor suppressor genes CDKN2A (a single gene that encodes two tumor suppressor proteins p16<sup>INK4A</sup> and p19<sup>ARF</sup>) or retinoblastoma (Rb), have been reported in metastatic melanoma [<xref ref-type="bibr" rid="CR9">9</xref>]. Recent studies demonstrated that <italic>p16</italic> protein loss was found in 50% of patients with familial melanomas [<xref ref-type="bibr" rid="CR10">10</xref>] and was associated with high proliferative activity (as measured by Ki-67 staining) [<xref ref-type="bibr" rid="CR11">11</xref>]. New agents targeting these cell cycle regulatory mechanisms may be useful in the treatment of melanoma.</p>
              <p>UCN-01 (7-hydroxystaurosporine), a derivative of the serine/threonine kinase inhibitor staurosporine, was originally isolated from the culture broth of Streptomyces species as a protein kinase C-selective inhibitor [<xref ref-type="bibr" rid="CR12">12</xref>]. While UCN-01 is a potent inhibitor of certain PKC isoenzymes [<xref ref-type="bibr" rid="CR13">13</xref>], the precise mechanism of action for its antitumor activity is still not fully understood. Many clinical studies support the observation that UCN-01 causes arrest of cell cycle progression at G<sub>1</sub>/S phase and/or abrogation of arrest at G<sub>2</sub> phase at concentrations that reduce PKC activity [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref>], although the extent to which PKC inhibition contributes to these effects remains unknown. In addition, UCN-01 exerts its anticancer activity by induction of apoptosis and sensitization to DNA-damaging agents [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Several phase I studies of UCN-01 either as monotherapy or in combination with cytotoxic agents have been reported [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR26">26</xref>]. One partial response lasting 8 months was reported in a patient with refractory metastatic melanoma enrolled in a single agent phase I trial of UCN-01 [<xref ref-type="bibr" rid="CR20">20</xref>]. UCN-01 administered as a 3-h infusion every 3 weeks led to higher dose intensity (mg/m<sup>2</sup>/h) and less toxicity compared to a 72-h infusion in a phase I study in patients with advanced solid tumors [<xref ref-type="bibr" rid="CR19">19</xref>]. The primary objective of this single-arm phase II study was to assess the anti-tumor activity of UCN-01 monotherapy as determined by the response rate in metastatic melanoma with intended correlative target validation.</p>
            </sec>
            <sec id="Sec2">
              <title>Patients and methods</title>
              <sec id="Sec3">
                <title>Eligibility</title>
                <p>Patients were required to have histologically or cytologically confirmed diagnosis of melanoma that was incurable by other means such as surgery, radiotherapy or limb perfusion. Patients were required to have none or one prior chemotherapy regimen and/or two or less biological therapies for metastatic disease. At least 4 weeks must have elapsed since prior therapy (6 weeks for nitrosoureas or mitomycin C) and the patient must have recovered from all toxicities attributable to prior therapy. Additional key inclusion criteria included: at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) [<xref ref-type="bibr" rid="CR27">27</xref>], age ≥18 years, life expectancy of greater than 4 months, Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; and adequate end-organ function. Patients with known brain metastases were eligible only if disease was controlled and patient was asymptomatic and not receiving corticosteroids.</p>
                <p>This trial was reviewed, approved, and sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (ClinicalTrials.gov, identifier NCT00072189) under a contract (N01 CM17101) with the California Cancer Consortium. The local institutional review board at each participating institution approved the protocol. All patients gave written, informed consent.</p>
              </sec>
              <sec id="Sec4">
                <title>Treatment protocol</title>
                <p>UCN-01 was provided to the NCI under a Clinical Trials Agreement (CTA) between Kyowa Hakko Kogyo Company, Ltd. and the NCI Division of Cancer Treatment and Diagnosis. UCN-01 was given at 90 mg/m<sup>2</sup> over 3 h on cycle 1, reduced to 45 mg/m<sup>2</sup> over 3 h for subsequent cycles. One cycle was defined as 21 days.</p>
              </sec>
              <sec id="Sec5">
                <title>Evaluation of response and toxicity</title>
                <p>All patients underwent computed tomography (CT) of the chest and abdomen within 4 weeks of registration. Tumor response was assessed every 3 weeks by clinical examination and every two cycles by CT using RECIST. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 2.0. For patients who experienced grade 3–4 toxicity, the UCN-01 was held until resolution to grade 0–1, then resumed in the next cycle with a one-dose level reduction (to 36 mg/m<sup>2</sup> for the first reduction and to 27 mg/m<sup>2</sup> for the second reduction).</p>
              </sec>
              <sec id="Sec6">
                <title>Statistical considerations</title>
                <p>A two-stage design was used in this study, with response rate as the primary efficacy endpoint. Secondary endpoints included overall survival (OS), progression-free survival (PFS), and toxicity. Pharmacodynamic correlates were planned to evaluate whether target inhibition (i.e., disruption of G1 phase progression) was achievable. All eligible patients were included in the efficacy analysis, and all treated patients were included in the safety analysis. The study assumed that a true response rate &gt;20% would warrant further study of this regimen, while a true response rate of &lt;5% would not warrant further study. Using this design, the probability of correctly declaring that an agent with a true response rate of 20% warranted further study was 0.91 (power). The probability of declaring that an agent with only a 5% true response rate warranted further study was 0.08 (alpha). In the first stage of accrual, 17 evaluable patients were to be enrolled and assessed. If no response was observed, then accrual would stop, with the conclusion that the regimen was not promising for further study in these patients. If one or more responses were seen in the first 17 patients, an additional 16 patients would be accrued in the second stage. Four or more responses out of 33 would be considered evidence that the regimen warrants further study, provided that other factors such as toxicity and survival also appeared favorable. PFS was defined as the time from registration until disease progression or death without documented progression disease. OS was defined as the time from registration until death. Patients who died without documentation of progression were considered to have progressed on the date of their death. The time to event distributions were estimated using the Kaplan-Meier method. All p-values were two-sided with statistical significance evaluated at the 0.05 alpha level.</p>
              </sec>
              <sec id="Sec7">
                <title>Correlative studies</title>
                <p>It was hypothesized that the efficacy of UCN-01 in melanoma would be dependent on the status of specific G1-phase cell cycle regulators. Further, it was hypothesized that UCN-01 activity could be seen in surrogate tissues (specifically buccal mucosal cells) and that melanoma response to UCN-01 could be monitored through surrogate markers in patient plasma, specifically secreted IL-6 or shed tumor methylated <italic>p16</italic> DNA. It was thought that patients with tumors having low p27 expression, low Ki-67 expression, loss of RB, hypermethylation of the p16 promotor, would be less responsive to UCN-01. Figure <xref rid="Fig1" ref-type="fig">1</xref> illustrates the schema for correlative studies.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Schema of the study</p></caption><graphic xlink:href="10637_2010_9562_Fig1_HTML" id="MO1"/></fig>
</p>
                <sec id="d32e478">
                  <title>Immunohistochemical (IHC) staining</title>
                  <p>Pretreatment formalin-fixed, paraffin-embedded (FFPE) diagnostic specimens were obtained and analyzed for the expression of the expression of p27, Ki-67, RB and pRB by routine IHC. The commercially available antibodies included: RB (antibody clone mAB245, Chemicon International, Inc.); phosphorylated-RB (sc-7986 goat polyclonal; Santa Cruz Biotechnology); underphosphorylated-Rb (antibody clone mAB549; Chemicon International, Inc.); p27<sup>Kip1</sup> (antibody clone DCS72; Oncogene Science); Ki-67 (Mib1 antibody; AMAC, Westbrook, ME). Both percentage of positive cells (from 1% to 100%) and intensity of staining (from 0 to 3+) were scored using the positive control tissues as 3+. Total score was established by multiplying the percentage by intensity, giving scores of 0–300. Final scores of 0, 1, 2, and 3 were given for total scores of 0, 1–50, 50–100, and 100–300, respectively. For p27, tumors staining positive in less than 40% of cells were scored as abnormal for p27.</p>
                </sec>
                <sec id="d32e486">
                  <title>Buccal mucosal cells</title>
                  <p>Surrogate epithelial cells from buccal brushings were obtained from selected patients prior to UCN-01 treatment and at 24hs and 48 h following initiation of UCN-01 treatment. Buccal mucosa was scraped with a brush and then transferred to a slide. Slides were fixed with 4% paraformaldehyde solution for 20 min then stored in 70% ethanol. These specimens were analyzed for p27 expression by IHC as described above, using beta-actin expression as internal control.</p>
                </sec>
                <sec id="d32e491">
                  <title>Tumor DNA and protein in plasma</title>
                  <p>Blood draws at pre-treatment and at the start of the second and third cycles of UCN-01 treatment were obtained for analyses of plasma proteins and shed tumor DNA. Blood samples were processed within 2 h after drawing. Plasma were assayed for levels of IL-6 using a commercially available ELISA kit (R&amp;D Systems, Minneapolis, MN). The methylation status of p16 promoter were determined using the CpG WIZ™ Amplification Kit assay (Intergen Co. Purchase, NY), which was a two-part assay that detects unmethylated <italic>p16</italic> promoter in one tube and any methylated <italic>p16</italic> promoter in another reaction.</p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec8" sec-type="results">
              <title>Results</title>
              <sec id="Sec9">
                <title>Patient characteristics</title>
                <p>Between 11/04/2003 and 12/13/2004, seventeen eligible patients were accrued to the first stage of the study. Further accrual was terminated after no responses were seen in this initial cohort. Table <xref rid="Tab1" ref-type="table">1</xref> summarizes the baseline demographic and clinical characteristics of these patients.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics and clinical characteristics of study patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Baseline characteristics</th><th>No.</th><th>%</th></tr></thead><tbody><tr><td>Patients evaluable/enrolled</td><td>16/17</td><td>94</td></tr><tr><td>Gender: Female %</td><td>11</td><td>65</td></tr><tr><td colspan="3">Age at enrollment, years</td></tr><tr><td> Median</td><td>53</td><td/></tr><tr><td> Range</td><td>34–85</td><td/></tr><tr><td colspan="3">Race/Ethnicity</td></tr><tr><td> White</td><td>13</td><td>76</td></tr><tr><td> Hispanic</td><td>3</td><td>18</td></tr><tr><td> Asian</td><td>1</td><td>6</td></tr><tr><td colspan="3">ECOG performance status</td></tr><tr><td> 0</td><td>10</td><td>59</td></tr><tr><td> 1</td><td>6</td><td>35</td></tr><tr><td> 2</td><td>1</td><td>6</td></tr><tr><td colspan="3">Primary malignant melanoma</td></tr><tr><td> Skin</td><td>14</td><td>82</td></tr><tr><td> Esophagus</td><td>1</td><td>6</td></tr><tr><td> Peritonium</td><td>1</td><td>6</td></tr><tr><td> Unknown</td><td>1</td><td>6</td></tr><tr><td colspan="3">Primary histology</td></tr><tr><td> Malignant melanoma, NOS</td><td>13</td><td>76</td></tr><tr><td> Nodular melanoma</td><td>3</td><td>18</td></tr><tr><td> Malignant melanoma in junction nevus</td><td>1</td><td>6</td></tr><tr><td colspan="3">Sites of metastatic disease</td></tr><tr><td> M1a: skin, subcutaneous or lymph nodes</td><td>4</td><td>24</td></tr><tr><td> M1b: lung</td><td>13</td><td>76</td></tr><tr><td> M1c: distant organs</td><td>14</td><td>82</td></tr><tr><td colspan="3">No. of metastatic sites</td></tr><tr><td> 1</td><td>3</td><td>18</td></tr><tr><td> 2</td><td>4</td><td>24</td></tr><tr><td> 3</td><td>5</td><td>29</td></tr><tr><td> &gt;3</td><td>5</td><td>29</td></tr><tr><td colspan="3">Prior adjuvant/Neoadjuvant therapy</td></tr><tr><td> Surgery</td><td>17</td><td>100</td></tr><tr><td> Radiation</td><td>3</td><td>18</td></tr><tr><td> Immunotherapy (alpha interferon)</td><td>5</td><td>29</td></tr><tr><td colspan="3">Prior metastatic therapy</td></tr><tr><td> Surgery</td><td>0</td><td>0</td></tr><tr><td> Radiation</td><td>0</td><td>0</td></tr><tr><td> Chemotherapy/Molecularly targeted agents</td><td>15</td><td>88</td></tr><tr><td colspan="3">Chemotherapy</td></tr><tr><td> 0</td><td>7</td><td>41</td></tr><tr><td> 1</td><td>6</td><td>36</td></tr><tr><td> 2</td><td>4</td><td>24</td></tr><tr><td colspan="3">Molecularly targeted agents</td></tr><tr><td> 0</td><td>8</td><td>48</td></tr><tr><td> 1</td><td>9</td><td>54</td></tr><tr><td>Immunotherapy</td><td>9</td><td>53</td></tr><tr><td>Vaccine</td><td>1</td><td>6</td></tr></tbody></table></table-wrap>
</p>
              </sec>
              <sec id="Sec10">
                <title>Efficacy</title>
                <p>Of the 17 patients, one patient was inevaluable for response due to early withdrawal after acute abdominal pain deemed unlikely related to treatment. No objective response was observed. Four (24%) patients had stable disease after more than two cycles of treatment, and 12 (71%) patients had disease progression. All 16 evaluable patients had disease progression before death. Median PFS was 1.3 months (95% CI, 1.2–3.0; range 0.7–9.5 months). Sixteen of the 17 eligible patients had died at the time of this report. The follow-up time for the early withdrawal patient, who had been subsequently treated with temozolomide, was over 5 years at the time of data cut-off on March 25, 2010. The median OS was 7.3 months (95% CI, 3.4–18.4; range 2.4–61.8 months). One-year survival rate was 41% and two-year survival rate was 12%. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows the Kaplan-Meier curves of PFS and OS for all 17 patients.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier curves of progression-free survival (<bold>A</bold>) and overall survival (<bold>B</bold>) in all 17 patients</p></caption><graphic xlink:href="10637_2010_9562_Fig2_HTML" id="MO2"/></fig>
</p>
              </sec>
              <sec id="Sec11">
                <title>Treatment administered and adverse effects</title>
                <p>A total of 54 cycles of treatment was given to the 17 eligible patients, with a median number of two cycles (rang, 1–18). Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the possibly, probably, or definitely treatment-related adverse events in all 17 patients who received at least one dose of treatment. The most common toxicities included hyperglycemia (<italic>N</italic> = 11, 65%), nausea (<italic>N</italic> = 9, 53%), anemia (<italic>N</italic> = 7, 41%), fatigue (<italic>N</italic> = 6, 35%), vomiting (<italic>N</italic> = 5, 29%), and pain (<italic>N</italic> = 4, 24%). Grade 3 treatment-related toxicities include hyperglycemia (<italic>N</italic> = 2), fatigue (<italic>N</italic> = 1), and diarrhea (<italic>N</italic> = 1) and one patient experienced grade 4 creatinine elevation and grade 4 anemia possibly due to UCN-01. No dose modifications were required as these patients had disease progression.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Treatment-related adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Adverse event</th><th colspan="2">Grades 1 or 2</th><th colspan="2">Grade 3</th><th colspan="2">Grade 4</th><th colspan="2">Any grade</th></tr><tr><th>(<italic>N</italic> = 17)</th><th>No. of patients</th><th>%</th><th>No. of patients</th><th>%</th><th>No. of patients</th><th>%</th><th>No. of patients</th><th>%</th></tr></thead><tbody><tr><td colspan="9">Hematologic</td></tr><tr><td> Anemia</td><td>6</td><td>35</td><td/><td/><td>1</td><td>6</td><td>7</td><td>41</td></tr><tr><td> Neutropenia</td><td>3</td><td>18</td><td/><td/><td/><td/><td>3</td><td>18</td></tr><tr><td> Lymphopenia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Thrombocytopenia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Gastrointestinal</td></tr><tr><td> Nausea</td><td>9</td><td>53</td><td/><td/><td/><td/><td>9</td><td>53</td></tr><tr><td> Vomiting</td><td>5</td><td>29</td><td/><td/><td/><td/><td>5</td><td>29</td></tr><tr><td> Diarrhea</td><td>2</td><td>12</td><td>1</td><td>6</td><td/><td/><td>3</td><td>18</td></tr><tr><td> Dehydration</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Constipation</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Abdominal pain*</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Constitutional</td></tr><tr><td> Fatigue</td><td>5</td><td>29</td><td>1</td><td>6</td><td/><td/><td>6</td><td>35</td></tr><tr><td> Anorexia</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Fever</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Metabolic</td></tr><tr><td> Hyperglycemia</td><td>9</td><td>53</td><td>2</td><td>12</td><td/><td/><td>11</td><td>65</td></tr><tr><td> Hypomagnesemia</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Hypermagnesemia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Hyponatremia</td><td>3</td><td>18</td><td/><td/><td/><td/><td>3</td><td>18</td></tr><tr><td> Hypocalcemia</td><td>3</td><td>18</td><td/><td/><td/><td/><td>3</td><td>18</td></tr><tr><td> Hypokalemia</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Hypophosphatemia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Hypoalbuminemia</td><td>3</td><td>18</td><td/><td/><td/><td/><td>3</td><td>18</td></tr><tr><td> ALT, SGPT</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> AST, SGOT</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Hyperbilirubinemia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Hypercholesteremia</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Hypertriglyceridemia</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Hyperuricemia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Neurologic</td></tr><tr><td> Pain</td><td>4</td><td>24</td><td/><td/><td/><td/><td>4</td><td>24</td></tr><tr><td> Neuropathy, sensory</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr><tr><td> Dizziness</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td> Somnolence</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Renal</td></tr><tr><td> Creatinine</td><td>1</td><td>6</td><td/><td/><td>1</td><td>6</td><td>2</td><td>12</td></tr><tr><td colspan="9">Musculoskeletal</td></tr><tr><td> Musculoskeletal disorder</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Cardiovascular</td></tr><tr><td> Supraventricular and nodal arrhythmia</td><td>1</td><td>6</td><td/><td/><td/><td/><td>1</td><td>6</td></tr><tr><td colspan="9">Skin</td></tr><tr><td> Rash/desquamation</td><td>2</td><td>12</td><td/><td/><td/><td/><td>2</td><td>12</td></tr></tbody></table><table-wrap-foot><p>Patient #11 had severe abdominal pain shortly after starting the treatment, and was off the study as “unlikely” related to treatment.</p></table-wrap-foot></table-wrap>
</p>
              </sec>
              <sec id="Sec12">
                <title>Correlative studies</title>
                <p>Only pretreatment tumor specimens were collected, including 20 blood specimens and ten tumor biopsies that were performed 72 h after initiation of UCN-01 treatment (seven patients) and 16 buccal mucosa samples (six patients). Ten pre-treatment tumor specimens were analyzed for p27, ki-67, RB and p-RB expression by IHC. As shown in Table <xref rid="Tab3" ref-type="table">3</xref>, three patients had low p27 expression and two had high Ki-67 expression. Of four patients who had sufficient tumor specimens for the analyses of RB and pRB expression, two had no RB expression and none had pRB expression. Of note, except for one patient who did not have sufficient tumor specimen for the assessment of RB and pRB expression, all other six patients had at least one abnormal expression of these cell cycle markers.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of correlative studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient no.</th><th colspan="4">IHC</th><th colspan="3">IL-6 level (pg/mL) by ELISA</th></tr><tr><th>(<italic>N</italic> = 7)</th><th>p27</th><th>Ki-67</th><th>RB</th><th>p-RB</th><th>Pre-treatment</th><th>Pre-second treatment</th><th>At disease progression</th></tr></thead><tbody><tr><td>UCD-001</td><td>30%</td><td>30%</td><td>30%</td><td>0</td><td char="." align="char">1.8</td><td>–</td><td char="." align="char">12.5</td></tr><tr><td>UCD-002</td><td>0</td><td>50%</td><td>60%</td><td>0</td><td char="." align="char">110.5</td><td char="." align="char">328.7</td><td char="." align="char">213.2</td></tr><tr><td>UCD-003</td><td>90%</td><td>60%</td><td>–</td><td>–</td><td char="." align="char">0</td><td char="." align="char">0.3</td><td char="." align="char">10.9</td></tr><tr><td>UCD-004</td><td>80%</td><td>35%</td><td>0</td><td>0</td><td char="." align="char">6.3</td><td char="." align="char">7.8</td><td char="." align="char">16.7</td></tr><tr><td>UCD-005</td><td>90%</td><td>40%</td><td>–</td><td>–</td><td>–</td><td>–</td><td char="." align="char">–</td></tr><tr><td>UCD-006</td><td>100%</td><td>90%</td><td>–</td><td>–</td><td char="." align="char">2.6</td><td char="." align="char">5.0</td><td char="." align="char">6.0</td></tr><tr><td>UCD-007</td><td>0</td><td>10%</td><td>0</td><td>0</td><td char="." align="char">3.7</td><td char="." align="char">13.5</td><td char="." align="char">7.8</td></tr></tbody></table><table-wrap-foot><p><italic>IHC</italic> immunohistochemistry stain. <italic>ELISA</italic> Enzyme-Linked Immunosorbent Assay</p><p>The reported normal value for IL-6 was 4.3 pg/mL</p></table-wrap-foot></table-wrap>
</p>
                <p>Buccal mucosa samples were assayed for p27 expression by Western blot. No p27 expression was detected in these samples. Only two of the seven serum samples had sufficient tumor-shed serum DNA for assessing the methylation status of p16 promoter: patient 002 had methylated p16 (RB IHC 60% positive) and patient 004 had unmethylated p16 expression (RB IHC zero; <italic>data not shown</italic>). These data are consistent with the previous report that abnormalities of <italic>p16</italic> and <italic>RB</italic> genes, both constituents of the G1 checkpoint pathway, are mutually exclusive in clinical samples [<xref ref-type="bibr" rid="CR28">28</xref>]. Interleukin-6 (IL-6) is a pleiotropic cytokine that modulates gene expression in a number of target cell types, including melanoma cells. We observed that plasma IL-6 levels by ELISA were elevated by at least two folds in post-treatment samples compared to the pre-treatment samples, reflecting the progression of disease. Since no objective response was observed in this study, no statistical correlation could be performed.</p>
              </sec>
            </sec>
            <sec id="Sec13" sec-type="discussion">
              <title>Discussion</title>
              <p>Identification of genetic abnormalities in various components of signaling pathways involved in the initiation and progression of melanoma has provided potential new therapeutic targets. It is well known that cell cycle dysregulation, such as the control of G1 phase progression, contributes to the progression and therapeutic resistance of malignant tumors, including metastatic melanoma. Thus, cell cycle inhibitors have since been developed as possible anti-cancer agents. UCN-01 was one of the first cell cycle inhibitors evaluated in the clinical trials [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. It was thought to exert its antitumor effect by through several mechanisms, such as inhibition of PKC and CDKs and up-regulation of endogenous CDK inhibitors p21 and p27. These effects have been associated with loss in G1 CDK activity and RB dephosphorylation [<xref ref-type="bibr" rid="CR8">8</xref>]. In this study, we evaluated the clinical efficacy of UCN-01 in refractory, metastatic melanoma and found insufficient activity to warrant further study.</p>
              <p>Since no clinical activity was observed, appropriate correlative studies could not be pursued. However, analyses on limited pre-treatment samples confirmed that genetic abnormalities in key cell cycle components, such as low level of p27, RB or pRB expression, high Ki-67 expression, methylation of p16 promoter, are common in metastatic melanoma despite expected variation in individual patients. Consistent with a previous report that plasma IL-6 level is significantly higher in melanoma patients compared to those of healthy controls [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], we found that elevation of plasma IL-6 level is associated with disease progression, supporting that IL-6 might be used as a surrogate biomarker for disease progression and a valid target for the treatment of advanced melanoma.</p>
              <p>Although our trial failed to demonstrate single agent activity of UCN-01 in metastatic melanoma, it does not prohibit further clinical evaluation of agents targeting cell cycle dysregulation [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], either as a single agent or in combination with other therapeutics. Recent breakthroughs in targeting BRAF mutation and breaking down the barriers to tumor tolerance/immunity by an antibody against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) hold great promise to improve the treatment for this deadly disease [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgement</title>
              <p>Supported by: NIH N01 CM62209 (Gandara), UL1 RR024146 from the National Center for Research Resources (Li), and the American Cancer Society Institutional Research Grant 95-125-07 (Li). We thank Dr. Paul H. Gumerlock for performing the correlative studies, supported by 22XS070 TO 02.</p>
              <sec id="d32e2151">
                <title>Open Access</title>
                <p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
              </sec>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Jemal A et al (2010) Cancer Statistics, 2010. CA Cancer J Clin</mixed-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barth</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wanek</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Morton</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic factors in 1, 521 melanoma patients with distant metastases</article-title>
                  <source>J Am Coll Surg</source>
                  <year>1995</year>
                  <volume>181</volume>
                  <issue>3</issue>
                  <fpage>193</fpage>
                  <lpage>201</lpage>
                  <?supplied-pmid 7670677?>
                  <pub-id pub-id-type="pmid">7670677</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tawbi</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Buch</surname>
                      <given-names>SC</given-names>
                    </name>
                  </person-group>
                  <article-title>Chemotherapy resistance abrogation in metastatic melanoma</article-title>
                  <source>Clin Adv Hematol Oncol</source>
                  <year>2010</year>
                  <volume>8</volume>
                  <issue>4</issue>
                  <fpage>259</fpage>
                  <lpage>266</lpage>
                  <?supplied-pmid 20505649?>
                  <pub-id pub-id-type="pmid">20505649</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mouawad</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Treatment for metastatic malignant melanoma: old drugs and new strategies</article-title>
                  <source>Crit Rev Oncol Hematol</source>
                  <year>2010</year>
                  <volume>74</volume>
                  <issue>1</issue>
                  <fpage>27</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.critrevonc.2009.08.005</pub-id>
                  <?supplied-pmid 19781957?>
                  <pub-id pub-id-type="pmid">19781957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Chapman</surname>
                      <given-names>PB</given-names>
                    </name>
                  </person-group>
                  <article-title>The history and future of chemotherapy for melanoma</article-title>
                  <source>Hematol Oncol Clin North Am</source>
                  <year>2009</year>
                  <volume>23</volume>
                  <issue>3</issue>
                  <fpage>583</fpage>
                  <lpage>597</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.hoc.2009.03.006</pub-id>
                  <?supplied-pmid 19464604?>
                  <pub-id pub-id-type="pmid">19464604</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Middleton</surname>
                      <given-names>MR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma</article-title>
                  <source>J Clin Oncol</source>
                  <year>2000</year>
                  <volume>18</volume>
                  <issue>1</issue>
                  <fpage>158</fpage>
                  <lpage>166</lpage>
                  <?supplied-pmid 10623706?>
                  <pub-id pub-id-type="pmid">10623706</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hodi</surname>
                      <given-names>FS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title>
                  <source>N Engl J Med</source>
                  <year>2010</year>
                  <volume>363</volume>
                  <issue>8</issue>
                  <fpage>711</fpage>
                  <lpage>723</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id>
                  <?supplied-pmid 20525992?>
                  <pub-id pub-id-type="pmid">20525992</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sauroja</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Analysis of G(1)/S checkpoint regulators in metastatic melanoma</article-title>
                  <source>Genes Chromosom Cancer</source>
                  <year>2000</year>
                  <volume>28</volume>
                  <issue>4</issue>
                  <fpage>404</fpage>
                  <lpage>414</lpage>
                  <pub-id pub-id-type="doi">10.1002/1098-2264(200008)28:4&lt;404::AID-GCC6&gt;3.0.CO;2-P</pub-id>
                  <?supplied-pmid 10862049?>
                  <pub-id pub-id-type="pmid">10862049</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>High</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>WA</given-names>
                    </name>
                  </person-group>
                  <article-title>Genetic mutations involved in melanoma: a summary of our current understanding</article-title>
                  <source>Adv Dermatol</source>
                  <year>2007</year>
                  <volume>23</volume>
                  <fpage>61</fpage>
                  <lpage>79</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.yadr.2007.07.009</pub-id>
                  <?supplied-pmid 18159896?>
                  <pub-id pub-id-type="pmid">18159896</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palmieri</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group</article-title>
                  <source>Br J Cancer</source>
                  <year>2000</year>
                  <volume>83</volume>
                  <issue>12</issue>
                  <fpage>1707</fpage>
                  <lpage>1714</lpage>
                  <pub-id pub-id-type="doi">10.1054/bjoc.2000.1513</pub-id>
                  <?supplied-pmid 11104570?>
                  <pub-id pub-id-type="pmid">11104570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vuhahula</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Straume</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Akslen</surname>
                      <given-names>LA</given-names>
                    </name>
                  </person-group>
                  <article-title>Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans</article-title>
                  <source>Anticancer Res</source>
                  <year>2000</year>
                  <volume>20</volume>
                  <issue>6C</issue>
                  <fpage>4857</fpage>
                  <lpage>4862</lpage>
                  <?supplied-pmid 11205232?>
                  <pub-id pub-id-type="pmid">11205232</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takahashi</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>UCN-01, a selective inhibitor of protein kinase C from Streptomyces</article-title>
                  <source>J Antibiot (Tokyo)</source>
                  <year>1987</year>
                  <volume>40</volume>
                  <issue>12</issue>
                  <fpage>1782</fpage>
                  <lpage>1784</lpage>
                  <pub-id pub-id-type="pmid">3429345</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Takahashi</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C</article-title>
                  <source>J Pharmacol Exp Ther</source>
                  <year>1990</year>
                  <volume>255</volume>
                  <issue>3</issue>
                  <fpage>1218</fpage>
                  <lpage>1221</lpage>
                  <?supplied-pmid 2262903?>
                  <pub-id pub-id-type="pmid">2262903</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Akiyama</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation</article-title>
                  <source>Jpn J Cancer Res</source>
                  <year>1999</year>
                  <volume>90</volume>
                  <issue>12</issue>
                  <fpage>1364</fpage>
                  <lpage>1372</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1349-7006.1999.tb00721.x</pub-id>
                  <?supplied-pmid 10665655?>
                  <pub-id pub-id-type="pmid">10665655</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Akiyama</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells</article-title>
                  <source>Cancer Res</source>
                  <year>1997</year>
                  <volume>57</volume>
                  <issue>8</issue>
                  <fpage>1495</fpage>
                  <lpage>1501</lpage>
                  <?supplied-pmid 9108451?>
                  <pub-id pub-id-type="pmid">9108451</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abe</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery</article-title>
                  <source>Jpn J Cancer Res</source>
                  <year>2001</year>
                  <volume>92</volume>
                  <issue>5</issue>
                  <fpage>537</fpage>
                  <lpage>545</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1349-7006.2001.tb01127.x</pub-id>
                  <?supplied-pmid 11376563?>
                  <pub-id pub-id-type="pmid">11376563</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fuse</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Review of UCN-01 development: a lesson in the importance of clinical pharmacology</article-title>
                  <source>J Clin Pharmacol</source>
                  <year>2005</year>
                  <volume>45</volume>
                  <issue>4</issue>
                  <fpage>394</fpage>
                  <lpage>403</lpage>
                  <pub-id pub-id-type="doi">10.1177/0091270005274549</pub-id>
                  <?supplied-pmid 15778420?>
                  <pub-id pub-id-type="pmid">15778420</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kurata</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01</article-title>
                  <source>Cancer Chemother Pharmacol</source>
                  <year>1999</year>
                  <volume>44</volume>
                  <issue>1</issue>
                  <fpage>12</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="doi">10.1007/s002800050939</pub-id>
                  <?supplied-pmid 10367744?>
                  <pub-id pub-id-type="pmid">10367744</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dees</surname>
                      <given-names>EC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <issue>2 Pt 1</issue>
                  <fpage>664</fpage>
                  <lpage>671</lpage>
                  <?supplied-pmid 15701854?>
                  <pub-id pub-id-type="pmid">15701854</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sausville</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms</article-title>
                  <source>J Clin Oncol</source>
                  <year>2001</year>
                  <volume>19</volume>
                  <issue>8</issue>
                  <fpage>2319</fpage>
                  <lpage>2333</lpage>
                  <?supplied-pmid 11304786?>
                  <pub-id pub-id-type="pmid">11304786</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lara</surname>
                      <given-names>PN</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <issue>12</issue>
                  <fpage>4444</fpage>
                  <lpage>4450</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2602</pub-id>
                  <?supplied-pmid 15958629?>
                  <pub-id pub-id-type="pmid">15958629</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hotte</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study</article-title>
                  <source>Ann Oncol</source>
                  <year>2006</year>
                  <volume>17</volume>
                  <issue>2</issue>
                  <fpage>334</fpage>
                  <lpage>340</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdj076</pub-id>
                  <?supplied-pmid 16284058?>
                  <pub-id pub-id-type="pmid">16284058</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jimeno</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors</article-title>
                  <source>Cancer Chemother Pharmacol</source>
                  <year>2008</year>
                  <volume>61</volume>
                  <issue>3</issue>
                  <fpage>423</fpage>
                  <lpage>433</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00280-007-0485-9</pub-id>
                  <?supplied-pmid 17429623?>
                  <pub-id pub-id-type="pmid">17429623</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Welch</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium</article-title>
                  <source>Gynecol Oncol</source>
                  <year>2007</year>
                  <volume>106</volume>
                  <issue>2</issue>
                  <fpage>305</fpage>
                  <lpage>310</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.02.018</pub-id>
                  <?supplied-pmid 17537491?>
                  <pub-id pub-id-type="pmid">17537491</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Fracasso PM et al (2010) A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kummar</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas</article-title>
                  <source>Cancer Chemother Pharmacol</source>
                  <year>2010</year>
                  <volume>65</volume>
                  <issue>2</issue>
                  <fpage>383</fpage>
                  <lpage>389</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00280-009-1154-y</pub-id>
                  <?supplied-pmid 19894051?>
                  <pub-id pub-id-type="pmid">19894051</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Therasse</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2000</year>
                  <volume>92</volume>
                  <issue>3</issue>
                  <fpage>205</fpage>
                  <lpage>216</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/92.3.205</pub-id>
                  <?supplied-pmid 10655437?>
                  <pub-id pub-id-type="pmid">10655437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rodolfo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pierotti</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Parmiani</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>A merging duo in melanoma formation</article-title>
                  <source>J Invest Dermatol</source>
                  <year>2005</year>
                  <volume>125</volume>
                  <issue>6</issue>
                  <fpage>xii</fpage>
                  <lpage>xiii</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23965.x</pub-id>
                  <?supplied-pmid 16354173?>
                  <pub-id pub-id-type="pmid">16354173</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lazar-Molnar</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Autocrine and paracrine regulation by cytokines and growth factors in melanoma</article-title>
                  <source>Cytokine</source>
                  <year>2000</year>
                  <volume>12</volume>
                  <issue>6</issue>
                  <fpage>547</fpage>
                  <lpage>554</lpage>
                  <pub-id pub-id-type="doi">10.1006/cyto.1999.0614</pub-id>
                  <?supplied-pmid 10843728?>
                  <pub-id pub-id-type="pmid">10843728</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Porter</surname>
                      <given-names>GA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes</article-title>
                  <source>Ann Surg Oncol</source>
                  <year>2001</year>
                  <volume>8</volume>
                  <issue>2</issue>
                  <fpage>116</fpage>
                  <lpage>122</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10434-001-0116-3</pub-id>
                  <?supplied-pmid 11258775?>
                  <pub-id pub-id-type="pmid">11258775</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sausville</surname>
                      <given-names>EA</given-names>
                    </name>
                  </person-group>
                  <article-title>Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies</article-title>
                  <source>Curr Med Chem Anticancer Agents</source>
                  <year>2003</year>
                  <volume>3</volume>
                  <issue>1</issue>
                  <fpage>47</fpage>
                  <lpage>56</lpage>
                  <pub-id pub-id-type="doi">10.2174/1568011033353560</pub-id>
                  <?supplied-pmid 12678914?>
                  <pub-id pub-id-type="pmid">12678914</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Senderowicz</surname>
                      <given-names>AM</given-names>
                    </name>
                  </person-group>
                  <article-title>Inhibitors of cyclin-dependent kinase modulators for cancer therapy</article-title>
                  <source>Prog Drug Res</source>
                  <year>2005</year>
                  <volume>63</volume>
                  <fpage>183</fpage>
                  <lpage>206</lpage>
                  <pub-id pub-id-type="doi">10.1007/3-7643-7414-4_8</pub-id>
                  <?supplied-pmid 16265881?>
                  <pub-id pub-id-type="pmid">16265881</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">Flaherty KT, McArthur G (2010) BRAF, a target in melanoma: implications for solid tumor drug development. Cancer</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
